IL-1α secreted by subcapsular sinus macrophages promotes melanoma metastasis in the sentinel lymph node by upregulating STAT3 signaling in the tumor

During melanoma metastasization, tumor cells originated in the skin migrate via lymphatic vessels to the sentinel lymph node (sLN) in a process that facilitates their spread across the body. Here, we characterized the innate inflammatory responses to melanoma metastasis in the sLN. For this purpose, we confirmed the migration of fluorescent metastatic melanoma cells to the sLN and we characterized the inflammatory response in the metastatic microenvironment. We found that macrophages located in the subcapsular sinus (SSM), produce pro-tumoral IL-1α after recognition of tumor antigens. Moreover, we confirmed that the administration of an anti-IL-1α depleting antibody reduced metastasis. Conversely, the administration of recombinant IL-1α accelerated the lymphatic spreading of the tumor. Additionally, the elimination of the macrophages significantly reduced the progression of the metastatic spread. To understand the mechanism of action of IL-1α in the context of the lymph node microenvironment, we applied single-cell RNA sequencing to dissected metastases obtained from animals treated with an anti-IL-1α blocking antibody. Amongst the different pathways affected, we identified STAT3 as one of the main targets of IL-1α signaling in metastatic cells. Moreover, we found that the anti-IL-1α anti-tumoral effect was not mediated by lymphocytes, as IL-1R1 KO mice did not show any improvement in metastasis growth. Finally, we found a synergistic anti-metastatic effect of the combination of IL-1α blocking and the STAT3 inhibitor (STAT3i) stattic. In summary, we described a new mechanism by which SSM support melanoma metastasis, highlighting a new target for immunotherapy.

[1]  Ji Li,et al.  The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors , 2021, Frontiers in Immunology.

[2]  A. Leha,et al.  The sentinel node invasion level (SNIL) as a prognostic parameter in melanoma , 2021, Modern Pathology.

[3]  K. Kahnert,et al.  Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study , 2021, Scientific Reports.

[4]  B. Becher,et al.  CD169+ lymph node macrophages have protective functions in mouse breast cancer metastasis. , 2021, Cell reports.

[5]  M. Spitzer,et al.  Systemic immunity in cancer , 2021, Nature Reviews Cancer.

[6]  T. Nakayama,et al.  CD169 Expression on Lymph Node Macrophages Predicts in Patients With Gastric Cancer , 2021, Frontiers in Oncology.

[7]  T. Padera,et al.  Progression of Metastasis through Lymphatic System , 2021, Cells.

[8]  Damián E. Blasi,et al.  Dogs display owner-specific expectations based on olfaction , 2021, Scientific Reports.

[9]  P. Allavena,et al.  Tumor-associated myeloid cells: diversity and therapeutic targeting , 2021, Cellular & Molecular Immunology.

[10]  André F. Rendeiro,et al.  STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway , 2020, Oncogene.

[11]  S. Coffelt,et al.  Emerging immunotherapies for metastasis , 2020, British journal of cancer.

[12]  Yi-Wen Chang,et al.  STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT–MET switch and cancer metastasis , 2020, Oncogene.

[13]  F. Ghiringhelli,et al.  Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency , 2020, Cancers.

[14]  G. Lesinski,et al.  Lymph Node Subcapsular Sinus Microenvironment-On-A-Chip Modeling Shear Flow Relevant to Lymphatic Metastasis and Immune Cell Homing , 2020, iScience.

[15]  P. Ascierto,et al.  Evolving impact of long-term survival results on metastatic melanoma treatment , 2020, Journal for ImmunoTherapy of Cancer.

[16]  G. Coukos,et al.  Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. , 2020, The Lancet. Oncology.

[17]  M. Kanda,et al.  Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer , 2020, Molecular Cancer.

[18]  C. Hoeller The future of combination therapies in advanced melanoma , 2020, memo - Magazine of European Medical Oncology.

[19]  S. Morrison,et al.  Lymph protects metastasizing melanoma cells from ferroptosis , 2020, Nature.

[20]  P. Marchetti,et al.  Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions , 2020, Journal of immunology research.

[21]  David S. Park,et al.  MCL-1Matrix maintains neuronal survival by enhancing mitochondrial integrity and bioenergetic capacity under stress conditions , 2020, Cell Death & Disease.

[22]  Bin Liu,et al.  Activation of STAT3 is a key event in TLR4 signaling-mediated melanoma progression , 2020, Cell Death & Disease.

[23]  K. D. de Visser,et al.  Immune crosstalk in cancer progression and metastatic spread: a complex conversation , 2020, Nature Reviews Immunology.

[24]  J. Wernberg,et al.  Epidemiology and Risk Factors of Melanoma. , 2020, The Surgical clinics of North America.

[25]  M. Fernö,et al.  Co-localization of CD169+ macrophages and cancer cells in lymph node metastases of breast cancer patients is linked to improved prognosis and PDL1 expression , 2020, Oncoimmunology.

[26]  Beom K. Choi,et al.  Siglec1-expressing subcapsular sinus macrophages provide soil for melanoma lymph node metastasis , 2019, eLife.

[27]  R. Krause,et al.  Characterization of the Dynamic Behavior of Neutrophils Following Influenza Vaccination , 2019, Front. Immunol..

[28]  J. Crecente‐Campo,et al.  Design of polymeric nanocapsules to improve their lympho-targeting capacity. , 2019, Nanomedicine.

[29]  T. Ashizawa,et al.  Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status. , 2019, Immunology letters.

[30]  J. Bergh,et al.  STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer , 2019, Cancers.

[31]  Paul J. Hoffman,et al.  Comprehensive Integration of Single-Cell Data , 2018, Cell.

[32]  Min Zhang,et al.  Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma , 2019, Front. Immunol..

[33]  S. Thomas,et al.  Material design for lymph node drug delivery , 2019, Nature Reviews Materials.

[34]  Junfeng Zhang,et al.  Targeting Lymph Node Sinus Macrophages to Inhibit Lymph Node Metastasis , 2019, Molecular therapy. Nucleic acids.

[35]  C. Garlanda,et al.  Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. , 2019, Immunity.

[36]  P. Spellman,et al.  Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets , 2019, Cancer cell.

[37]  S. Liao,et al.  Lymph Node Subcapsular Sinus Macrophages as the Frontline of Lymphatic Immune Defense , 2019, Front. Immunol..

[38]  G. Koh,et al.  Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation , 2019, Science.

[39]  Keisha N. Hardeman,et al.  Quantifying Drug Combination Synergy along Potency and Efficacy Axes. , 2019, Cell systems.

[40]  Y. Carmi,et al.  Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti–PD-1 for tumor abrogation , 2018, Proceedings of the National Academy of Sciences.

[41]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[42]  I. Melero,et al.  Cytokines in clinical cancer immunotherapy , 2018, British Journal of Cancer.

[43]  Chengying Mao,et al.  A Comprehensive Algorithm for Evaluating Node Influences in Social Networks Based on Preference Analysis and Random Walk , 2018, Complex..

[44]  J. Luke,et al.  T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection , 2018, Cancer Immunology Research.

[45]  David Herrmann,et al.  Recent advances in understanding the complexities of metastasis , 2018, F1000Research.

[46]  Paul Hoffman,et al.  Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.

[47]  Z. Bago-Horvath,et al.  Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice , 2018, Science.

[48]  Eelco F. J. Meijer,et al.  Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice , 2018, Science.

[49]  Jennifer R. Grandis,et al.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.

[50]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[51]  D. Fabbro,et al.  PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy , 2017, Clinical Cancer Research.

[52]  C. Logsdon,et al.  The immune system in cancer metastasis: friend or foe? , 2017, Journal of Immunotherapy for Cancer.

[53]  E. Blackstone,et al.  Cancer of the esophagus and esophagogastric junction—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[54]  J. Fuxe,et al.  Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic system , 2017, Molecular oncology.

[55]  J. Pollard,et al.  Repolarizing macrophages improves breast cancer therapy , 2017, Cell Research.

[56]  Antonio Lanzavecchia,et al.  Macrophage Death following Influenza Vaccination Initiates the Inflammatory Response that Promotes Dendritic Cell Function in the Draining Lymph Node. , 2017, Cell reports.

[57]  A. Bhardwaj,et al.  In situ click chemistry generation of cyclooxygenase-2 inhibitors , 2017, Nature Communications.

[58]  P. Mohanty,et al.  MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. , 2017, The Lancet. Oncology.

[59]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[60]  J. Luke,et al.  Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma , 2016, Proceedings of the National Academy of Sciences.

[61]  Grace X. Y. Zheng,et al.  Massively parallel digital transcriptional profiling of single cells , 2016, Nature Communications.

[62]  B. Lippitz,et al.  Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis , 2016, Oncoimmunology.

[63]  C. Dinarello,et al.  Reduction in C‐reactive protein indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved survival in early stage multiple myeloma , 2016, American journal of hematology.

[64]  Melissa M. Sprachman,et al.  SCS macrophages suppress melanoma by restricting tumor-derived vesicle–B cell interactions , 2016, Science.

[65]  P. Mohanty,et al.  Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer , 2015, Investigational New Drugs.

[66]  M. Detmar,et al.  Intravital and Whole-Organ Imaging Reveals Capture of Melanoma-Derived Antigen by Lymph Node Subcapsular Macrophages Leading to Widespread Deposition on Follicular Dendritic Cells , 2015, Front. Immunol..

[67]  A. Bruckbauer,et al.  Inflammation-induced disruption of SCS macrophages impairs B cell responses to secondary infection , 2015, Science.

[68]  M. Kuka,et al.  Annals of the New York Academy of Sciences the Role of Lymph Node Sinus Macrophages in Host Defense , 2022 .

[69]  E. Bruera,et al.  MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. , 2014, The Lancet. Oncology.

[70]  T. Fehm,et al.  Quantitative Measurement of Melanoma Spread in Sentinel Lymph Nodes and Survival , 2014, PLoS medicine.

[71]  M. Skobe,et al.  Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses , 2013, The Journal of experimental medicine.

[72]  Y. Carmi,et al.  Unique Versus Redundant Functions of IL-1α and IL-1β in the Tumor Microenvironment , 2013, Front. Immunol..

[73]  E. Voronov,et al.  The transcription of the alarmin cytokine interleukin-1 alpha is controlled by hypoxia inducible factors 1 and 2 alpha in hypoxic cells , 2012, Front. Immun..

[74]  Elizabeth E Gray,et al.  Lymph Node Macrophages , 2012, Journal of Innate Immunity.

[75]  P. Ott,et al.  Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node , 2012, Modern Pathology.

[76]  Yasunobu Miyake,et al.  CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. , 2011, Immunity.

[77]  M. Bosenberg,et al.  Decoding Melanoma Metastasis , 2010, Cancers.

[78]  Siamon Gordon,et al.  Capture of influenza by medullary dendritic cells via SIGN-R1 is essential for humoral immunity in draining lymph nodes , 2010, Nature Immunology.

[79]  S. Whelan,et al.  Subcapsular Sinus Macrophages Prevent CNS Invasion Upon Peripheral Infection With a Neurotropic Virus , 2010, Nature.

[80]  T. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[81]  A. Dispenzieri,et al.  Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. , 2009, Mayo Clinic proceedings.

[82]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[83]  F. Batista,et al.  B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. , 2007, Immunity.

[84]  Y. Carmi,et al.  The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions , 2006, Cancer and Metastasis Reviews.

[85]  A. Mantovani,et al.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.

[86]  Ulrik Brandes,et al.  Centrality Measures Based on Current Flow , 2005, STACS.

[87]  M. Newman A measure of betweenness centrality based on random walks , 2003, Soc. Networks.

[88]  H. Wiley,et al.  Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. , 2001, Journal of the National Cancer Institute.

[89]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[90]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[91]  A. Sher,et al.  Analysis of Fractalkine Receptor CX3CR1 Function by Targeted Deletion and Green Fluorescent Protein Reporter Gene Insertion , 2000, Molecular and Cellular Biology.

[92]  Masatoshi Suzuki,et al.  Production of Mice Deficient in Genes for Interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 Receptor Antagonist Shows that IL-1β Is Crucial in Turpentine-induced Fever Development and Glucocorticoid Secretion , 1998, The Journal of experimental medicine.

[93]  P. Morrissey,et al.  Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. , 1997, Journal of immunology.

[94]  A. Ben-Baruch Organ selectivity in metastasis: regulation by chemokines and their receptors , 2007, Clinical & Experimental Metastasis.

[95]  G. Chartrand Introductory Graph Theory , 1984 .